Login to Your Account


Bacterial immunotherapy shows promise in tumor-targeting

By John Fox
Staff Writer

Wednesday, February 15, 2017

A nonvirulent tumor-targeting bacterial strain bioengineered to release multiple Toll-like receptor (TLR) ligands was shown to suppress tumor growth and prolong survival in mouse tumor models in a Korean study, suggesting it could be a new cancer immunotherapy in humans.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription